Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UB-421 add-on to ART in stabilized HIV-1 patients
NCT03743376Phase 2Completed
- Sponsor
- United BioPharma
- Start
- Dec 2018
- Primary completion
- Oct 2020
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of semzuvolimab in human immunodeficiency virus type 1 infection (HIV-1) (3 arms), sponsored by United BioPharma. Primary endpoint: Treatment related Treatment-Emergent Adverse Events at 48 weeks. Started Dec 2018; status: completed.
02
Drugs
semzuvolimab
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03743376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03743376.